The increase in survival seen in mice treated with TMZ and CRAd-S-pk7 combination was accompanied by a decrease in the expression of Ki-67, suggesting a decrease in proliferation of live glioma cells treated with this therapeutic combination (Figure 5A and B). The gene discussed is MKI67; the disease is central nervous system cancer.